West Nile Virus: A pathogen of concern for older adults

Geriatrics and Aging

Volumn 9, Issue 7, 2006, Pages 465-471

  Drebot, Michael A ^a   Artsob, Harvey ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Diagnosis; Disease prevention; Epidemiology; Neurological illness; West Nile virus

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; DIETHYLTOLUAMIDE; DNA VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; PERMETHRIN; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER DERIVATIVE; RIBAVIRIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIROTHERAPY AGENT; WEST NILE VACCINE;

ANTIBODY DETECTION; ARTICLE; CENTRAL AMERICA; CLINICAL FEATURE; CLINICAL TRIAL; ELDERLY CARE; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; NORTH AMERICA; PREVALENCE; PUBLIC HEALTH; REHYDRATION; RISK ASSESSMENT; RISK REDUCTION; SOUTH AMERICA; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

EID: 33846047833     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mackenzie JS, Barrett ADT, Deubel V. The Japanese encephalitis serological group of flaviviruses: a brief introduction to the group. In: Mackenzie JS, Barrett ADT, Deubel V, eds. Japanese Encephalitis and West Nile Viruses. New York: Springer-Verlag, 2002:1-10.
2. Smithburn KC, Hughes TP, Burke AW, et al. A neurotropic virus isolaled from the blood of a native of Uganda. Am J Trop Med 1940;20:471-92.
3. Drebot MA, Lindsay R, Barker I, et al. West Nile virus surveillance and diagnostics: a Canadian perspective. Can J Infect Dis 2003;14:105-14.
4. Granwehr BP, Lillibridge KM, Higgs S, et al. West Nile virus, where are we now? Lancet Infect Dis 2004;4:547-56.
5. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in fire United States. Annu Rev Med 2006;57:181-94.
6. Landotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999;286:2333-7.
7. West Nile virus surveillance information - Public Health Agency of Canada http://www.phac-aspc.gc.ca/wnv-vwn/index.html.
8. CDD. Division of vector-borne infectious diseases. West Nile virus. http://www.cdc.gov/ncidod/dvbid/westnile/index.htm.
9. Provisional Surveillance Summary of the West Nile Virus. MMWR Morb Mortal Wkly Pep 2002;51:1129-33.
10. Sibbald B. Canada will check donor blood for West Nile virus if test available. CMAJ 2003;168:207.
11. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-2203.
12. Teperman LW, Diflo T, Fahmy A, et al. West Nile virus infections in organ transplant recipients. MMWR Morb Mortal Wkly Rep 2005;54:1-3.
13. Health Canada Guidance Document: Measures to Prevent West Nile Virus Transmission Through Cells, Tissues and Organs for Transplantation and Assisted Reproduction 2004; http://www.hc-sc.gc.ca/hpfb-dgpsa/bgtd-dpbtg/ wnv2004_ctoguidance_e.html
14. Petersen LR, Martin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002;137:173-9.
15. Penn RG, Guarner J, Sejvar JJ, et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Infect Dis 2006;42:680-83.
16. Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005;11:1174-9.
17. Sejvar, JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003;290:511-15.
18. Watsan JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004;141:360-5.
19. Klee AL, Maldin B, Edwin B, et al. Long term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004;10:1405-11.
20. Pepperall C, Rau N, Krajden S et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in south-central Ontario. CMAJ 2003;168:1399-405.
21. Kumar D, Drebot MA, Wong SJ, et al. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant. 2004;4:1883-8.
22. Yakub I, Lillibridge KM, Moran A, et al. Single nucleolide polymorphisms in genes for 2′5′-oligoadenylate synthetase and Rnase L in palients hospitalized with West Nile virus infection. J Infect Dis 2005;192:1741-8.
23. Tilley PAG, Walle R, Chow A, et al. Clinical utility of commercial enzyme immunoassays during the inaugural season of West NIle virus activity, Alberta, Canada. J Clin Microbiol 2005;43:4691-5.
24. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immonoglobulin M antibody in confirmed West NIle virus encephalitis cases. Emerg Infect Dis 2003:9:376-9.
25. Levett PN, Sonnenberg K, Sidaway F, et al. Use of IgG avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol 2005;43:5873-5.
26. Landotti RS, Kerst AJ, Nasal RS, et al. Rapid detection of West Nile virus from human clinical specimens, field collected mosquitoes, and avian samples by a TaqMan reverse-transcriptase-PCR assay. J Clin Microbiol 2000;38:4066-71.
27. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002;8:107-8.
28. Bai F, Wang T, Pal U, et al. Use of RNA interference to prevent lethal murine West Nile virus infection. J Infect Dis 2005;7:1148-54.
29. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005;8:4599-609.
30. Agrawal AG, Petersen LR. Human immunoglobulin as a treatment for West Nile virus infection. J Infect Dis 2003;188:1-4.
31. Hall RA, Khromykh AA. West Nile virus vaccines. Expert Opin Biol Ther 2004;4:1295-305.
32. Arroyo J, Miller C, Catalan J, et al. Chimer Vax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficaccy. J Virol 2004;78:12497-507.
33. Shapiro H, Micucci S. Pesticide use for West Nile virus. CMAJ 2003:168:1427-30.
34. Lóeb M, Elliot S, Fearon M, et al. Risk factors for West Nile virus infections: Results of an Ontario serosurvey. Emerg Infect Dis 2005;11:1433-6.
35. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002;347:13-18